ReviewCancer drug resistance (Alhambra, Calif.)2022

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer.

Ahmed M Elshazly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.